Advertisement

Principles of Medical Treatment

  • Candace S. BrownEmail author
  • Candi C. Bachour
  • Gloria A. Bachmann
Chapter

Abstract

Acute and chronic vulvar conditions are noted in women throughout their life span. Several of these conditions, such as vulvar infections and intraepithelial neoplasia, have well-defined clinical pathways of treatment utilizing pharmacologic interventions that have been vetted through clinical trials. Others, such as vulvodynia, a chronic pain condition that has been recognized for over 100 years, continue to perplex clinicians regarding best options for pharmacologic intervention. This chapter will review the spectrum of pharmacologic interventions used in various vulvar conditions, with an emphasis on the ones used in the management of vulvodynia. Vulvodynia will be highlighted as it is a vulvar condition clinicians treat with scant data from clinical trials.

References

  1. 1.
    American College of Obstetricians and Gynecologists. Vulvar disorders. ACOG clinical updates in women’s health care. VIII ed. Washington, DC: ACOG; 2010. p. 36.Google Scholar
  2. 2.
    Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-3):1–137.Google Scholar
  3. 3.
    Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of a Women’s sexual health and the North American Menopause Society. Menopause. 2014;10:1063–8.CrossRefGoogle Scholar
  4. 4.
    Danby CS, Margesson LJ. Approach to the diagnosis and treatment of vulvar pain. Dermatol Ther. 2010;23:485–504.CrossRefGoogle Scholar
  5. 5.
    Shifren JL, Gass ML. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038–62.CrossRefGoogle Scholar
  6. 6.
    Bornstein J, Goldstein AT, Stockdale CK, et al. 2015 ISSVD, ISSWSH and IPPS consensus terminology and classification of persistent vulvar pain and Vulvodynia. Obstet Gynecol. 2016;127(4):745–51.CrossRefGoogle Scholar
  7. 7.
    Harlow BL, Kunitz CG, Nguyen RHN, Rydell SA, Turner RM, MacLehose RF. Prevalence of symptoms consistent with a diagnosis of vulvodynia: population-based estimates from 2 geographic regions. Am J Obstet Gynecol. 2014;210:40.e1–8.CrossRefGoogle Scholar
  8. 8.
    Jasmin L, Tien D, Janni G, et al. Is noradrenaline a significant factor in the analgesic effect of antidepressants? Pain. 2003;106:3–8.CrossRefGoogle Scholar
  9. 9.
    Foster DC, Kotok MB, Huang L, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol. 2010;116:583–93.CrossRefGoogle Scholar
  10. 10.
    Brown CS, Wan J, Bachmann G, et al. Self-management, amitriptyline, and amitriptyline plus triamcinolone in the management of vulvodynia. J Women’s Health. 2009;18:163–9.CrossRefGoogle Scholar
  11. 11.
    Reed BD, Caron AM, Gorenflo DW, et al. Treatment of vulvodynia with tricyclic antidepressants: efficacy and associated factors. J Low Genit Tract Dis. 2006;10:245–51.CrossRefGoogle Scholar
  12. 12.
    De Andres J, Sanchis-Lopez N, Asensio-Samper JM, et al. Vulvodynia—an evidence-based literature review and proposed treatment algorithm. Pain Pract. 2015;16(2):204–36.CrossRefGoogle Scholar
  13. 13.
    Pagano R, Wong S. Use of amitriptyline cream in the management of entry dyspareunia due to provoked vestibulodynia. J Low Genit Tract Dis. 2012;16:394–7.CrossRefGoogle Scholar
  14. 14.
    Nyirjesy P, Lev-Sagie A, Mathew L, Culhane JF. Topical amitriptyline-baclofen cream for the treatment of provoked vestibulodynia. J Low Genit Tract Dis. 2009;13:230–6.CrossRefGoogle Scholar
  15. 15.
    Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10:685–92.CrossRefGoogle Scholar
  16. 16.
    Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol. 2008;112:579–85.CrossRefGoogle Scholar
  17. 17.
    Brown CS, Foster DC, Wan JY, Rawlinson L, Bachmann GA, GABA Study Group. Rationale and design of a multicenter randomized clinical trial of extended release gabapentin in provoked vestibulodynia and biological correlates of response. Contemp Clin Trials. 2013;36:154–65.CrossRefGoogle Scholar
  18. 18.
    Cummins TR. Setting up for the block: the mechanism underlying lidocaine’s use-dependent inhibition of sodium channels. J Physiol. 2007;582(Pt 1):11.CrossRefGoogle Scholar
  19. 19.
    Zolnoun DA, Hartmann KE, Steege JF. Overnight 5% lidocaine ointment for treatment of vulvar vestibulitis. Obstet Gynecol. 2003;102:84–7.PubMedGoogle Scholar
  20. 20.
    Danielsson I, Torstensson T, Brodda-Jansen G, Bohm-Starke N. EMG biofeedback versus topical lidocaine gel: a randomized study for the treatment of women with vulvar vestibulitis. Acta Obstet Gynecol Scan. 2006;85:1360–7.CrossRefGoogle Scholar
  21. 21.
    Rapkin AJ, McDonald JS, Morgan M. Multilevel local anesthetic nerve blockade for the treatment of vulvar vestibulitis syndrome. Amer J Obstet Gynecol. 2008;198:41.e1–5.CrossRefGoogle Scholar
  22. 22.
    McDonald JS, Rapkin AJ. Multilevel local anesthetic nerve blockade for the treatment of generalized vulvodynia: a pilot study. J Sex Med. 2012;9:2919–26.CrossRefGoogle Scholar
  23. 23.
    Murina F, Tassan P, Roberti P, Bianco V. Treatment of vulvar vestibulitis with submucous infiltrations of methylprednisolone and lidocaine: an alternative approach. J Reprod Med. 2001;46:713–6.PubMedGoogle Scholar
  24. 24.
    Tympanidis P, Casula MA, Yiangou Y, Terenghi G, Dowd P, Anand P. Increased vanilloid receptor VR1 innervation in vulvodynia. Eur J Pain. 2004;8:129–33.CrossRefGoogle Scholar
  25. 25.
    Murina F, Radici G, Bianco V. Capsaicin and the treatment of vulvar vestibulitis syndrome: a valuable alternative? Med Gen Med. 2004;6:48.Google Scholar
  26. 26.
    Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin a reduces formalin-induced pain. Pain. 2004;107:125–33.CrossRefGoogle Scholar
  27. 27.
    Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A—a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med. 2009;6:2523–37.CrossRefGoogle Scholar
  28. 28.
    Pelletier F, Parratte B, Penze S, Moreno JP, Aubin F, Humbert P. Efficacy of high doses of botulinum toxin a for treating provoked vestibulodynia. Brit J Dermatol. 2011;164:617–22.Google Scholar
  29. 29.
    Foster DC, Hadsday JD. Elevated tissue levels of interleukin-1 beta and tumor necrosis factor-alpha in vulvar vestibulitis. Obstet Gynecol. 1997;89:291–6.CrossRefGoogle Scholar
  30. 30.
    Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage 1a expression and interleukin 1 production. J Immunol. 1982;129:1803–5.PubMedGoogle Scholar
  31. 31.
    Munday PE. Treatment of vulval vestibulitis with a potent topical steroid. Sex Transm Infect. 2004;80:154–5.CrossRefGoogle Scholar
  32. 32.
    Desrochers G, Bergeron S, Khalife S, Dupuis M-J, Jodoin M. Provoked vestibulodynia: psychological predictors of topical and cognitive-behavioral treatment outcome. Behav Res Ther. 2010;48:106–15.CrossRefGoogle Scholar
  33. 33.
    Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011;25:491–502.CrossRefGoogle Scholar
  34. 34.
    Bornstein J, Abramovici H. Combination of subtotal perineoplasty and interferon for the treatment of vulvar vestibulitis. Gynecol Obstet Investig. 1997;44:53–6.CrossRefGoogle Scholar
  35. 35.
    Marinoff SC, Turner ML, Hirsch RP, Richard G. Intralesional alpha interferon: cost effective therapy for vulvar vestibulitis syndrome. J Reprod Med. 1993;38:19–24.PubMedGoogle Scholar
  36. 36.
    Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Small MJ, Gelone SP. Cromolyn cream for recalcitrant idiopathic vulvar vestibulitis: results of a placebo-controlled study. Sex Transm Inf. 2001;77:53–7.CrossRefGoogle Scholar
  37. 37.
    Donders GG, Bellen G. Cream with cutaneous fibroblast lysate for the treatment of provoked vestibulodynia: a double-blind randomized placebo-controlled crossover study. J Lower Genital Tract Dis. 2012;16:427–36.CrossRefGoogle Scholar
  38. 38.
    Kamdar N, Fisher L, MacNeill C. Improvement in vulvar vestibulitis with montelukast. J Reprod Med. 2007;52:912–6.PubMedGoogle Scholar
  39. 39.
    Farajun Y, Zarfati D, Abramov L, Livoff A, Bornstein J. Enoxaparin treatment of vulvodynia. A randomized controlled trial. Obstet Gynecol. 2012;120:565–73.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Candace S. Brown
    • 1
    Email author
  • Candi C. Bachour
    • 1
  • Gloria A. Bachmann
    • 2
  1. 1.University of Tennessee Health Science CenterMemphisUSA
  2. 2.Rutgers-Robert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations